560 Immunotherapeutic and antimetastatic activity of LTX-315 in preclinical models of ICI-resistant...
560 Immunotherapeutic and antimetastatic activity of LTX-315 in preclinical models of ICI-resistant breast cancer
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundOncolytic peptides are attractive tools for the development of novel anticancer regimens [1]. LTX-315 is a synthetic peptide with a marked capacity to elicit tumor-targeting immunity in preclinical cancer models [2]. Indeed, LTX-315 has been shown to elicit immunogenic cell death (ICD) in malignant cells [3, 4] and to deplete immunosuppre...
Alternative Titles
Full title
560 Immunotherapeutic and antimetastatic activity of LTX-315 in preclinical models of ICI-resistant breast cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_1b44ce167572402abc4aa806a1f5f6eb
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1b44ce167572402abc4aa806a1f5f6eb
Other Identifiers
E-ISSN
2051-1426
DOI
10.1136/jitc-2021-SITC2021.560
